[go: up one dir, main page]

PE17598A1 - QUINOLINS - Google Patents

QUINOLINS

Info

Publication number
PE17598A1
PE17598A1 PE1996000810A PE00081096A PE17598A1 PE 17598 A1 PE17598 A1 PE 17598A1 PE 1996000810 A PE1996000810 A PE 1996000810A PE 00081096 A PE00081096 A PE 00081096A PE 17598 A1 PE17598 A1 PE 17598A1
Authority
PE
Peru
Prior art keywords
benzo
alkyl
quinolins
reaction
inhibitors
Prior art date
Application number
PE1996000810A
Other languages
Spanish (es)
Inventor
Rainer Luond
Villar Esteban Pombo
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE17598A1 publication Critical patent/PE17598A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIEREN A COMPUESTOS DE FORMULA (I), EN DONDE: "X" ES -O-, -S- o -N(CH3)-; R1 ES HIDROGENO O ALQUILO C1-C4; R2 ES ALQUILO C1-C4 O PIRIDILO. TAMBIEN SE REFIERE AL PROCEDIMIENTO DE OBTENCION DE (I), QUE COMPRENDE: 1) HACER REACCIONAR UN BENZO[c]TIADIAZOL, BENZO[c]FURAZAN o 2-METIL-2H-BENZO[d]TRIAZOL (SUSTITUIDOS EN LA POSICION 3 o 4 CON Q) CON UNA QUINOLINA (SUSTITUIDA EN LA POSICION 8 CON Q`), EN DONDE: Q Y Q' SON GRUPOS SALIENTES CAPACES DE PARTICIPAR EN UNA REACCION DE ACOPLAMIENTO CRUZADO; Y OPCIONALMENTE, 2) N-ALQUILAR o N-OXIDAR EL COMPUESTO (I). DICHAS QUINOLINAS ACTUAN COMO INHIBIDORES SELECTIVOS DE LA FOSFODIESTERASA IV Y/O INHIBIDORES DE LA LIBERACION DE TNF-O, SIENDO USADOS EN EL TRATAMIENTO DEL ASMA, O DE LAS ENFERMEDADES AUTOINMUNES, ENTRE OTRASTHEY REFER TO COMPOUNDS OF FORMULA (I), WHERE: "X" IS -O-, -S- or -N (CH3) -; R1 IS HYDROGEN OR C1-C4 ALKYL; R2 IS C1-C4 ALKYL OR PIRIDYL. IT ALSO REFERS TO THE PROCEDURE FOR OBTAINING (I), WHICH INCLUDES: 1) REACTION A BENZO [c] TIADIAZOL, BENZO [c] FURAZAN or 2-METHYL-2H-BENZO [d] TRIAZOL (REPLACED IN POSITION 3 or 4 WITH Q) WITH A QUINOLINE (SUBSTITUTED IN POSITION 8 WITH Q`), WHERE: QYQ 'ARE OUTGOING GROUPS ABLE TO PARTICIPATE IN A CROSS-COUPLED REACTION; AND OPTIONALLY, 2) N-RENT or N-OXIDIZE THE COMPOUND (I). SUCH QUINOLINS ACT AS SELECTIVE INHIBITORS OF PHOSPHODIESTERASE IV AND / OR INHIBITORS OF THE RELEASE OF TNF-O, BEING USED IN THE TREATMENT OF ASTHMA, OR OF AUTOIMMUNE DISEASES, AMONG OTHERS

PE1996000810A 1995-11-14 1996-11-12 QUINOLINS PE17598A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9523267.4A GB9523267D0 (en) 1995-11-14 1995-11-14 Organic compounds

Publications (1)

Publication Number Publication Date
PE17598A1 true PE17598A1 (en) 1998-04-06

Family

ID=10783856

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1996000810A PE17598A1 (en) 1995-11-14 1996-11-12 QUINOLINS

Country Status (17)

Country Link
EP (1) EP0873338A1 (en)
JP (1) JPH11515000A (en)
KR (1) KR19990067574A (en)
CN (1) CN1202170A (en)
AU (1) AU7570996A (en)
BR (1) BR9611504A (en)
CA (1) CA2235126A1 (en)
CO (1) CO4770973A1 (en)
CZ (1) CZ149498A3 (en)
GB (1) GB9523267D0 (en)
HU (1) HUP9903492A3 (en)
MX (1) MX9803839A (en)
PE (1) PE17598A1 (en)
PL (1) PL326636A1 (en)
SK (1) SK63998A3 (en)
TR (1) TR199800851T2 (en)
WO (1) WO1997018208A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU777012B2 (en) 1999-08-21 2004-09-30 Takeda Gmbh Synergistic combination of PDE inhibitors and beta 2 adrenoceptor agonist
US20040180900A1 (en) 2001-05-23 2004-09-16 Masaharu Takigawa Therapeutic composition for repairing chondropathy
KR20040007596A (en) 2001-05-23 2004-01-24 다나베 세이야꾸 가부시키가이샤 Compositions for promoting healing of bone fracture
JP2006522151A (en) 2003-04-01 2006-09-28 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ Phosphodiesterase inhibitors in infertility
KR20070026390A (en) 2004-01-23 2007-03-08 암젠 인코포레이션 Compound and how to use
JP2006347936A (en) 2005-06-15 2006-12-28 Bayer Cropscience Ag Insecticidal benzanilides
CA2796826A1 (en) 2010-05-10 2011-11-17 Gilead Sciences, Inc. Bifunctional quinoline derivatives
UY33373A (en) 2010-05-10 2011-12-30 Gilead Sciences Inc ? Bifunctional pyrazolopyridine compounds, their use in therapy and compositions that comprise them ?.
CA2888485C (en) 2012-10-16 2021-01-26 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of ror.gamma.t
ME02794B (en) 2012-10-16 2018-01-20 Janssen Pharmaceutica Nv METHYLENE-LINED CHINOLINYL MODULATORS OF ROR-GAMMA-T
AU2013331493A1 (en) 2012-10-16 2015-04-09 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORyt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
BR112016008215A2 (en) 2013-10-15 2017-09-26 Janssen Pharmaceutica Nv roryt alkyl-linked quinolinyl modulators
ES2742843T3 (en) 2013-10-15 2020-02-17 Janssen Pharmaceutica Nv ROR quinolinyl modulators (gamma) t
IL279410B2 (en) * 2018-06-24 2024-03-01 Adama Agan Ltd Process for the preparation of quinmerac

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9027055D0 (en) * 1990-12-13 1991-02-06 Sandoz Ltd Organic compounds
US5455252A (en) * 1993-03-31 1995-10-03 Syntex (U.S.A.) Inc. Optionally substituted 6,8-quinolines

Also Published As

Publication number Publication date
BR9611504A (en) 1999-03-02
JPH11515000A (en) 1999-12-21
HUP9903492A3 (en) 2000-08-28
SK63998A3 (en) 1998-10-07
CN1202170A (en) 1998-12-16
CO4770973A1 (en) 1999-04-30
HUP9903492A2 (en) 2000-07-28
MX9803839A (en) 1998-09-30
GB9523267D0 (en) 1996-01-17
TR199800851T2 (en) 1998-08-21
CZ149498A3 (en) 1998-08-12
PL326636A1 (en) 1998-10-12
CA2235126A1 (en) 1997-05-22
AU7570996A (en) 1997-06-05
EP0873338A1 (en) 1998-10-28
KR19990067574A (en) 1999-08-25
WO1997018208A1 (en) 1997-05-22

Similar Documents

Publication Publication Date Title
PE17598A1 (en) QUINOLINS
ES2175079T3 (en) INDOL DERIVATIVES USEFUL AS INHIBITORS OF CGMP-PDE.
DK274688D0 (en) ACTIVATION EX VIVO OF EFFECTOR CELLS FOR TARGETED CELL KILL
AR029383A1 (en) SMALL MOLECULES, THE INTERMEDIARIES FOR THEIR SYNTHESIS, THE PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE TO PREPARE A MEDICINAL PRODUCT INTENDED FOR TREATMENT OR PROPHYLAXIS OF INFLAMMATORY DISEASES OR MEDIATIONED BY IMMUNE CELLS
TR199901905T2 (en) 2- (P�rin-9-yl) -tetrahidrofuran-3,4-diol t�revleri.
DE3582452D1 (en) SUBSTITUTED BICYCLIC COMPOUNDS.
BR0113643A (en) Guanidinobenzamides compounds as mc4-r agonists and their uses
NZ325449A (en) Naphthyl-substituted benzimidazole derivatives as anticoagulants
TR199800585T2 (en) (Methylsulfonyl)Phenyl-2-(5H)-Furanons as COX-2 Inhibitors.
ES2040261T3 (en) PROCEDURE FOR PREPARING 6-FLUOR-4-OXO-1,4-DIHYDROKINOLINE-3-CARBOXYLIC ACIDS AND 9-FLUOR-3-METHYL-7-OXO-2,3-DIHYDRO-7H-PIRIDO (1,2, 3-DE) (1,4) BENZOXAZINA-6-CARBOXILICO SUBSTITUTED.
DK0970095T3 (en) Novel benzimidazoline inhibitors for fructose-1,6-bisphosphase
ES2194987T3 (en) USEFUL TRICICLIC COMPOUNDS TO INHIBIT THE FARNESIL-PROTEIN-TRANSFERASA.
ES2175087T3 (en) USEFUL TRICICLIC COMPOUNDS IN THE TREATMENT OF CELL PROLIFERATION DISORDERS.
ES2102154T3 (en) THROMBIN INHIBITION.
MD1688F2 (en) Benzothiophene, benzofuran and indolethiazepinons, oxazepinons and diazepinons, pharmaceutical composition, method of inhibiting the leucocytes adherence to the endothelial cells for inflammatory diseases treatment and method of treatment of the mammals affected by the HIV infection
GR3004980T3 (en)
ATE180781T1 (en) CRYSTALLINE TIAGABINE HYDROCHLORIDE MONOHYDRATE, ITS PREPARATION AND USE
ES2084339T3 (en) TETRAHIDROPIRIDINAS AND HIDROXIPIPERIDINAS SUBSTITUTED USEFUL AS AGENTS FOR THE CENTRAL NERVOUS SYSTEM.
PE29798A1 (en) ACETIDINS
LU83820A1 (en) 2-OXOAZETIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE
ES2060818T3 (en) DERIVATIVES OF INDOL, BENZOFURANO AND BENZOTIOFENO SUBSTITUTED AS INHIBITORS OF 5-LIPOOXIGENASA.
MX9306666A (en) NEW AZETIDINONES SUBSTITUTED AS ANTI-INFLAMMATORY AND ANTI-DEGENERATIVE AGENTS.
ES2143004T3 (en) DERIVATIVES FROM MILBEMICINE, ITS PREPARATION AND USE.
ES2131313T3 (en) NIPECOTIC ACID DERIVATIVES AS ANTITHROMBOTIC COMPOUNDS.
ES8303427A1 (en) "A PROCEDURE FOR PREPARING CEFEM COMPOUNDS".

Legal Events

Date Code Title Description
FA Abandonment or withdrawal